Immuno-oncology is revolutionizing cancer therapy, by training the immune system to attack tumor cells selectively. This offers a kind of precision, adaptability and endurance that traditional therapies simply can't match. Immuno-oncology applications range from CAR-T therapies, checkpoint inhibitors, and oncolytic viruses, but the intricate nature of immune interactions in the tumor microenvironment is an area of difficult research. Creative Biolabs responds to these concerns with a broad portfolio of immuno-oncology assays poised to advance the development of promising cancer immunotherapies.
Introduction
Immuno-oncology therapies engage the body's immune system on a cellular and molecular level, providing a potentially effective replacement for older cancer therapies that attack cancer cells. Accurate and continuous monitoring of immune activity and cell specificity is vital for assessing immunological responses in the microenvironment of a tumor. The live-cell analysis system by Creative Biolabs provides direct, in vitro monitoring of immune-cancer cell interactions, which allows immunotherapy development to draw on the most accurate data available. In contrast to static tests, this real-time method captures rapid fluctuations in immune cell behavior, which gives scientists a way to make data-driven drug development decisions.
Recent advancements, including CAR-T cell therapies, checkpoint inhibitors, and oncolytic viruses, demonstrate immuno-oncology's groundbreaking potential. Creative Biolabs augments these advances with advanced assays measuring immune function, antigen presentation and immune-mediated killing of tumor cells, each custom-built to the particular requirements of these new treatments, so you can move forward with the next phase of drug discovery.
Fig.1 A Schematic Representation of the Immunosuppressive TME.1
Featured Services
Tumor Cell Killing Assays
Target Expression Analysis
The drug affects tumor-specific antigen expression through target expression analysis that determines immune specificity. As it allows to determine what antigens can be found on the cancer cells, this test can be used to help target therapy targets effectively and prevent off-target side effects.
Antigen Presentation Assays
The T-cell activation against the tumor requires presentation of an antigen. Creative Biolabs assays study the effects of therapeutics on antigen presentation on immune cells to understand how they might be able to trigger immune responses (crucial for T-cell activation therapies).
Immune Cell-Mediated Cytotoxicity
Our cytotoxicity tests (ADCC, CDC, T-cell/NK cell-mediated killing) can evaluate whether immune cell activation-based therapies to kill cancer cells work. Such tests inform the design of immune therapies such as monoclonal antibodies and CAR-T drugs.
3D Spheroid and Organoid Models of Tumors
We create 3D tumor models that very closely mimic the tumor microenvironment including immune cell invasion and drug entry. Such models provide a more realistic environment to explore the behavior and effects of immune cells and help to make in vitro findings predictive in the clinic.
Immune Cell Assays
T-Cell Killing Assays
T-cell killing assays quantify the cytotoxic capacity of T cells to kill cancer cells directly, and can tell how well T cells can attack tumors. This assay is essential to treatments that use T-cell activity, such as CAR-T cells and checkpoint inhibitors.
NK Cell Killing Assays
Testing for natural killer (NK) cells measures the potential of NK cells to attack cancer cells, which is key to NK cell activation therapies. The NK cell cytotoxicity assays from Creative Biolabs enable us to see how treatments might boost innate immune responses to cancer.
Immune Activation Assays
We measure immune cell activation during therapy by our immune activation assays. These tests help us know how a drug modulates the immune system, finetuning therapies so they target as many immune cells as possible and have as few side effects as possible.
Immunophenotyping and Cell Profiling
Immunomarker Detection
The two basic approaches of immunomarkers for cancers and immune cells are flow cytometry (FACS) and immunohistochemistry (IHC). These methods can be used to define particular immune cell types and states that help understand the immune response in the tumor microenvironment and target immunotherapies.
Cytokine Analysis
Cytokine measurements track immune modulation and can assess inflammation, immune suppression, and activation. With the detection of cytokine production by platforms like Luminex, ELISA, and ELISPOT, Creative Biolabs can obtain valuable data about the immune response to the tumor for therapeutic assessment.
T-Cell Receptor Sequencing
T-cell receptor (TCR) sequencing provides precise T-cell numbers and phenotypes to identify biomarkers and treatments. Profiling TCR populations can help scientists determine immune activation and therapeutic response, and design therapies accordingly.
Cell Proliferation Assays
Proliferation tests count immune cell proliferation as an indicator of immune activation. These tests assess immune-cell responses against candidates in search of immune-generating drugs – an essential first step for early drug screening.
Our live-cell analysis platform increases the precision of data by monitoring immune reactions in real time for the assessment of therapeutic effects. This reduces variability and gives information that conventional methods cannot give, resulting in high-quality data that is clinically relevant.
Comprehensive Assay Portfolio
High-parameter immune phenotyping, tumor-infiltrating lymphocyte profiling, and functional assays are all offered at Creative Biolabs for every immunotherapy development stage. We have the breadth of tools that allow scientists to stitch together multiple data points for deeper and more consistent conclusions.
Reliable, Reproducible Data
Each of our assays is validated to ensure reproducibility and accuracy, providing reliable data critical for preclinical research and clinical translation. Our commitment to quality data supports researchers as they progress from discovery to clinical applications, delivering trustworthy results at every step.
With new treatments opening up new possibilities for patient care, immuno-oncology is opening up new frontiers in cancer therapy. Innovative immuno-oncology assay services from Creative Biolabs give precise data that enable these advances. From immune profiling to tumor cell killing assays, our assays aid scientists at every step and provide clear details on immune responses and therapies. Creative Biolabs is your trusted immuno-oncology partner that equips research institutions and biotech companies to create the next generation of cancer medicines. For more details, please feel free to contact us or send us a query directly.
Reference
Benavente, Sergi, et al. "Therapy-induced modulation of the tumor microenvironment: new opportunities for cancer therapies." Frontiers in oncology 10 (2020): 582884. Distributed under Open Access license CC BY 4.0, without modification.
Fig.1 A Schematic Representation of the Immunosuppressive TME.1
Immunoassay
Download our brochure